Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation

Tong-Xie-Yao-Fang (TXYF) has been widely used for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in traditional Chinese medicine. However, its mechanism of action in the treatment of IBS-D remains to be fully understood. Recent reports have shown that species in the gut can i...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 9; p. 1110
Main Authors Li, Junchen, Cui, Huantian, Cai, Yuzi, Lin, Jin, Song, Xin, Zhou, Zijun, Xiong, Wantao, Zhou, Huifang, Bian, Yuhong, Wang, Li
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.09.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tong-Xie-Yao-Fang (TXYF) has been widely used for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in traditional Chinese medicine. However, its mechanism of action in the treatment of IBS-D remains to be fully understood. Recent reports have shown that species in the gut can induce production in the colon, which then contributes to IBS-D. Due to the wide use of TXYF in the clinical treatment of IBS-D and the close relationship between gut microbiota and IBS-D, we hypothesize that TXYF treats IBS-D by modulating gut microbiota and regulating colonic levels. In this study, variation analysis of 16S rRNA was conducted to evaluate changes in the distribution of gut microbiota in IBS-D model rats after TXYF treatment. Moreover, we investigated whether TXYF could affect colonic levels in IBS-D model rats. We then performed fecal transplantation experiments to confirm the effects of TXYF on gut microbiota and levels. We found that TXYF treatment can ameliorate IBS-D and regulate levels in colon tissue homogenates. TXYF treatment also affected the diversity of gut microbiota and altered the relative abundance of and in gut flora populations. Finally, we showed that fecal transplantation from TXYF-treated rats could relieve IBS-D and regulate levels in colon tissue homogenates. In conclusion, the present study demonstrates that TXYF treatment diminishes colonic levels and alleviates the symptoms of IBS-D by favorably affecting microbiota levels in gut flora communities.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Fangyan Wang, Wenzhou Medical University, China; Fernando Ochoa-Cortes, Universidad Autónoma de San Luis Potosí, Mexico; Michael T. Bailey, The Ohio State University College of Medicine, United States
Edited by: Benedict Green, Agricultural Research Service (USDA), United States
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2018.01110